A Study of Mirikizumab in Participants With Plaque Psoriasis
I6T-MC-AMBP - ClinicalTrials.gov - NCT03718884
This study is known as a "drug interaction study". The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Plaque PsoriasisWhat the trial is testing?
Mirikizumab (LY3074828)Could I receive a Placebo?
NoEnrollment Goal
29Trial Dates
Oct 23, 2018 - Oct 28, 2019How long will I be in the trial?
The study will last about 23 weeks for each participant, which includes 10 outpatient visits and 2 inpatient visits (with 3 overnights per visit).Trial Phase
ILilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
You will complete the questionnaire on another website.YesNo